Vericel Corp

NASDAQ:VCEL   3:59:58 PM EDT
41.24
+1.09 (+2.72%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.92B
Current PE13,268.80
Forward PE 4124
2yr Forward PE 128.88
See more stats
Estimates Current Quarter
Revenue$44.73 Million
Adjusted EPS$0.21
See more estimates
10-Day MA$38.70
50-Day MA$29.44
200-Day MA$19.67
See more pivots

Vericel Corp Stock, NASDAQ:VCEL

64 SIDNEY ST., CAMBRIDGE, MA 02139
United States of America
Phone: 7349305555
Number of Employees: 216

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.